NuSep
Experts in protein discovery

FOR IMMEDIATE RELEASE

$1.5m Underwriting of the SPO & Investor Meetings

Sydney, Australia 22nd June 2011 - NuSep (ASX: NSP) Nusep wishes to advise the market that it has underwritten $1.5m of the recently announced SPO.

This $1.5m underwriting of the SPO includes $200,000 which has been underwritten by the NuSep Board. The balance of the $1.5m underwriting has been provided by NuSep's largest shareholders.

The $200,000 underwriting commitment by the NuSep Board is subject to shareholder approval which will be sought at the General Meeting to be held on Wednesday 31st August 2011.

The General Meeting of shareholders on Wednesday 31st August 2011 will also consider the following two other motions:

- Approval of the SPO to raise up to $2.1m for NuSep; and
- Approval of the 1:2 bonus issue of 15¢ share options with an exercise date of 31st March 2012.

In order to provide NuSep shareholders with additional information on the Company's activities the Company will hold the following investor presentations and one onsite presentation at NuSep's Lane Cove facilities.

Date & Time	Location
Monday 4th July 2011 at 12 noon	Melbourne at Level 26, 530 Collins Street, Melbourne
Tuesday 5th July 2011 at 12 noon	Sydney at Level 18, 133 Castlereagh St, Sydney
Thursday 21st July 2011 at 11am	NuSep Facility at 324 Burns Bay Rd, Lane Cove
Monday 25th July 2011 at 12 noon	Melbourne at Level 26, 530 Collins Street, Melbourne
Tuesday 26th July 2011 at 12 noon	Sydney at Level 18, 133 Castlereagh St, Sydney

Please advise the Company Secretary Prakash Patel at cosec@nusep.com if you wish to attend one or more of these presentations.

****ENDS****

For more information please contact:
Contact:
Prakash Patel
Company Secretary
+61 2 8415 7399
prakash.patel@nusep.com

NuSep Holdings Ltd
324 Burns Bay Rd
Lane Cove NSW 2066

Postal Address
P.O. Box 823
Lane Cove NSW 1595

Contact Details
Telephone +61 2 8415 7300
Facsimile +61 2 8415 7399

Email info@nusep.com
Web www.nusep.com
ABN 33 120 047 556

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from ***Fraction to Function***. The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world's first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

- **Gels** – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.
- **Separation Instruments** – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF and is expected to undergoing clinical trials later this year.
- **Proteomics Software** – NuSep offers the unique ProteoIQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.
- **Biological Products** – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company's website www.NuSep.com

About SingaPharm

SingaPharm is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. SingaPharm is currently a wholly owned subsidiary of NuSep Holdings Limited (ASX: NSP). SingaPharm's process is based on the **Pr**eparative **I**solation by **M**embrane **E**lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is 'electronically' driven membrane fractionation.

This process is flexible and modular compared with the large scale inflexible processing facilities of existing fractionators in US and Europe. The process has increased product yield relative to the existing process with increased product safety. The flexible nature of the PrIME technology also provides SingaPharm with access to plasma volumes that previously did not meet the criteria for larger scale processing facilities. Further, SingaPharm's process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.